Pulse Biosciences, Inc. (FRA:6L8)

Germany flag Germany · Delayed Price · Currency is EUR
11.60
-0.10 (-0.85%)
Last updated: Dec 1, 2025, 8:10 AM CET
-39.27%
Market Cap800.08M
Revenue (ttm)73.30K
Net Income (ttm)-63.69M
Shares Outn/a
EPS (ttm)-0.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open11.60
Previous Close11.70
Day's Range11.60 - 11.60
52-Week Range10.80 - 23.60
Betan/a
RSI36.15
Earnings DateMar 27, 2026

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-ena... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2014
Employees 75
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6L8
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.